Originally FROM MIMS:
Tagamet
PrintAdd to FavouritesCMITablets
Cimetidine
GlaxoSmithKline Australia Pty Ltd
MIMS Abbreviated Prescribing Information
Section: 1(a) Hyperacidity, reflux and ulcers
Consumer Medicine Information: Available
Pregnancy Category: B1
Sport Category: Permitted in sport
Uses/Indications: H2-antagonist. Short-term treatment of proven duodenal, gastric ulcer; maintenance in recurring duodenal ulcer after short-term therapy; maintenance less than or equal to 1 yr to reduce relapse risk in chronic benign gastric ulcer; short-term treatment (less than or equal to 12 wks) of persistent gastroesophageal reflux disease (GORD); symptomatic treatment (less than or equal to 2 wks) of GORD; treatment of gastrinoma (Zollinger-Ellison syndrome), scleroderma oesophagus
Contraindications: Concurrent dofetilide
Precautions: Excl malignancy; renal, hepatic impairment; haemodialysis; intubated ICU patients receiving mechanical ventilation; organic brain syndrome; high dose; chronic lung disease, diabetes, immunocompromised, elderly (incr risk community acquired pneumonia); pregnancy, lactation, children
Adverse Reactions: Headache; GI upset; tiredness, drowsiness; dizziness; hypersensitivity incl rash, anaphylaxis (rare); musculoskeletal pain; gynaecomastia, impotence (high dose); CV effects incl tachycardia (rare); others, see full PI
Drug Interactions: See Contra; CYP450 substrates (esp with narrow therapeutic index) incl coumarins, TCAs, class I antiarrhythmics, Ca channel blockers, oral sulfonylureas, phenytoin, theophylline, metoprolol; drugs affected by competition for renal tubular secretion eg procainamide, metformin, cyclosporin, tacrolimus; drugs affected by altered gastric pH eg atazanavir, some azole antifungals (eg ketoconazole, itraconazole, posaconazole); chemotherapeutic agents/ therapies eg carmustine, fluorouracil, epirubicin, radiation; narcotic analgesics eg morphine; myelosuppressants
TAGAMET (Tablets) Prescription required. S4
Cimetidine; pale green f-c;
Dose: May be taken with or without food. Acute duodenal, gastric ulcer: 800 mg at bedtime, or 400 mg morning and bedtime, or 200 mg 3 times daily and 400 mg at bedtime (4-8 wks); may incr to max 1.6 g/day. Maintenance recurrent duodenal ulcer: 400 mg at bedtime. Maintenance chronic benign gastric ulcer: 400 mg at bedtime for less than or equal to 1 yr. Zollinger-Ellison syndrome: 200 mg 3 times daily and 400 mg at bedtime; may incr to max 2 g/day. GORD: 800 mg at night or in divided doses for less than or equal to 12 wks; symptomatic therapy of GORD: 200 mg up to 4 times daily for less than or equal to 2 wks, max 800 mg/day. Scleroderma oesophagus: usually 1200 mg/day in divided doses. Renal impairment: reduce dose